Image Place holder

Hung T. Khong, MD


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt McKinley Outpatient Center
Overview

Cancer Types Treated: Breast Cancer, Ductal Carcinoma In Situ , Inflammatory Breast Cancer , Invasive Ductal Carcinoma , Triple Negative Breast Cancer

Dr. Khong's clinical interests include breast cancer and cancer immunotherapy.  He specializes in the treatment of breast cancer of all stages.  He is interested in combining treatment methods such as chemotherpy or radiotherapy with immunotherapy and chemotherapy with targeted therapy. Dr. Khong has developed several innovative clinical trials for the neoadjuvant treatment of stages II and II breast cancer, and first-line therapy for metastatic breast cancer.  He brings to Moffitt and innovative clinical trial that is the first in the country to combine endocrine therapy and checkpoint inhibitors in the neoadjuvant treatment of hormone-receptor positive breast cancer.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine

Fellowship:

  • National Cancer Institute - Medical Oncology
  • National Cancer Institute - Surgery Branch

Residency:

  • Baylor College of Medicine - Internal Medicine Program

Medical School:

  • Temple University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19803
A Phase II Trial With Safety Run-In Of Neoadjuvant Therapy With An Aromatase Inhibitor In Combination With Durvalumab (Medi4736) In Postmenopausal Patients With Hormone-Receptor-Positive Breast Cancer
Condition: Breast
Intervention: AMP-514 (Durvalumab); Anastrozole; Arimadex (Anastrozole); Aromasin (Exemestane); Durvalumab; Exemestane; Femara (Letrozole); Letrozole; MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18386
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Condition: Breast
Intervention: Not Applicable
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab; Taxol (paclitaxel); Trastuzumab; interferon gamma (Actimmune); paclitaxel; rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 18810
Phase 1b Study To Assess The Safety, Tolerability, and Clinical Activity of Gedatolisib in Combination with Palbociclib and Either Letrozole Or Fulvestrant in Women with Metastatic or Locally Advanced/Recurrent Breast Cancer (Mbc)
Condition: Breast
Intervention: 772256 (Palbociclib); Faslodex (fulvestrant); Femara (Letrozole); Gedatolisib; Letrozole; PF-05212384 (Gedatolisib); Palbociclib; fulvestrant
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A
Open

CLINICAL TRIAL 19462
An Open-Label, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors and Lymphomas
Condition: Multiple
Intervention: Bay 1895344
Open

CLINICAL TRIAL 19632
A Phase Ib/II, Open-Label, Multicenter,Randomized Umbrella Study Evaluating the Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab; Cobimetinib; Eribulin Mesylate; Gemzar (gemcitabine); Ipatasertib; Not Applicable; SGN-LIV1A; Xeloda (capecitabine); capecitabine; gemcitabine
Open

CLINICAL TRIAL 19765
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Condition: Breast
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 19646
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III
Condition: Breast
Intervention: Carvedilol; Not Applicable
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition: Multiple
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 19755
A Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid Plus Electroporation in Combination with Intravenous Pembrolizumab Therapy in Patients with Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); tavo-EP
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: Alimta (Pemetrexed); BMS-936558 (Nivolumab); Eribulin Mesylate; NKTR-214; Nab-paclitaxel (Abraxane); Nivolumab; Paraplatin (carboplatin); Pemetrexed; Taxol (paclitaxel); carboplatin; cisplatin; paclitaxel
Open

CLINICAL TRIAL 19820
A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: INCB086550
Open

CLINICAL TRIAL 19394
An Open-Label, Single-Arm Pilot Study Evaluating The Antitumor Activity And Safety Of Niraparib As Neoadjuvant Treatment In Localized, Her2-Negative, Brca-Mutant Breast Cancer Patients
Condition: Breast
Intervention: Niraparib
Open

CLINICAL TRIAL 19654
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses and Treatment Intensification of a Vaccine-Based Immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for Advanced Non-Small Cell Lung Cancer and Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: AdC68; CP-675,206 (tremelimumab); PF-06801591; pDNA; tremelimumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • West J, Robertson-Tessi M, Luddy K, Park DS, Williamson DFK, Harmon C, Khong HT, Brown J, Anderson ARA. The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. JCO Clin Cancer Inform. 2019 Feb;3:1-12. Pubmedid: 30742484.
  • Khong B, Lawson BO, Ma J, McGovern C, Van Atta JK, Ray A, Khong HT. Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2. BMC Cancer. 2018 Oct;18(1):1007. Pubmedid: 30342473. Pmcid: PMC6195987.
  • Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT. Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep. 2018 Mar;8(1):4044. Pubmedid: 29511262. Pmcid: PMC5840418.
  • Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D. Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res. 2017 Oct;27(5):477-484. Pubmedid: 28800031. Pmcid: PMC5583702.
  • Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT. A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer. 2017 Nov;17(7):503-509. Pubmedid: 28579139.
  • Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB, Khong HT. Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis. Oncotarget. 2017 May;8(19):32171-32189. Pubmedid: 28418870. Pmcid: PMC5458276.
  • Lawson BO, Khong HT. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature. Anticancer Res. 2017 Mar;37(3):1365-1368. Pubmedid: 28314304.
  • Bowen RC, Hahn AW, Butler TW, Khong HT. Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy. Mol Clin Oncol. 2017 Jan;6(1):122-124. Pubmedid: 28123744. Pmcid: PMC5245156.
  • Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2017 Aug;8(32):52413-52419. Pubmedid: 28881739. Pmcid: PMC5581038.
  • Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget. 2016 Sep;7(39):64390-64399. Pubmedid: 27391442. Pmcid: PMC5325451.
  • Liu Z, Smith KR, Khong HT, Huang J, Ahn EE, Zhou M, Tan M. miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20. Oncotarget. 2016 Nov;7(48):78667-78679. Pubmedid: 27637078. Pmcid: PMC5346668.
  • Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT. A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget. 2016 Dec. Pubmedid: 28039455.
  • Ray A, Khong B, Khong HT. A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer. Anticancer Res. 2016 Dec;36(12):6673-6676. Pubmedid: 27920001.
  • Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D. Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. J Am Acad Dermatol. 2014 Oct;71(4):835-838. Pubmedid: 25219711. Pmcid: PMC4167347.
  • Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M. miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. J Biol Chem. 2013 Feb;288(6):4334-4345. Pubmedid: 23255607. Pmcid: PMC3567684.
  • Andtbacka RH, Donaldson MR, Bowles TL, Bowen GM, Grossmann K, Khong H, Grossman D, Anker C, Florell SR, Bowen A, Duffy KL, Leachman SA, Noyes RD. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol. 2013 Feb;20(2):689-696. Pubmedid: 23054111.
  • Howell PM, Liu Z, Khong HT. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals (Basel). 2010 Jul;3(7):2022-2044. Pubmedid: 27713340. Pmcid: PMC4036667.
  • Wang Y, Radfar S, Liu S, Riker AI, Khong HT. Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma. BMC Med. 2010 Feb;8:14. Pubmedid: 20163701. Pmcid: PMC2839965.
  • Wang Y, Radfar S, Khong HT. Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha. BMC Cancer. 2010 Feb;10:60. Pubmedid: 20178622. Pmcid: PMC2843673.
  • Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 2009 Oct;28(42):3689-3701. Pubmedid: 19668225.
  • Radfar S, Wang Y, Khong HT. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol. 2009 Nov;183(10):6800-6807. Pubmedid: 19846868.
  • Barve M, Bender J, Senzer N, Cunningham C, Greco FA, McCune D, Steis R, Khong H, Richards D, Stephenson J, Ganesa P, Nemunaitis J, Ishioka G, Pappen B, Nemunaitis M, Morse M, Mills B, Maples PB, Sherman J, Nemunaitis JJ. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep;26(27):4418-4425. Pubmedid: 18802154.
  • Riker AI, Radfar S, Liu S, Wang Y, Khong HT. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther. 2007 Mar;7(3):345-358. Pubmedid: 17309326.
  • Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother. 2005 Nov;28(6):551-559. Pubmedid: 16224272.
  • Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005 Feb;26(2):111-117. Pubmedid: 15668127. Pmcid: PMC1388277.
  • Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, Yu JS. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 2005 Aug;24(33):5226-5234. Pubmedid: 15897911.
  • Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol. 2005 Apr;174(7):4415-4423. Pubmedid: 15778407. Pmcid: PMC2174604.
  • Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma. J Immunother. 2003 Jul;26(4):301-312. Pubmedid: 12843792.
  • Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002 Nov;3(11):999-1005. Pubmedid: 12407407. Pmcid: PMC1508168.
  • Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002 Jun;62(11):3020-3023. Pubmedid: 12036907. Pmcid: PMC2561957.
  • Khong HT, Rosenberg SA. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol. 2002 Jan;168(2):951-956. Pubmedid: 11777994. Pmcid: PMC2430890.
  • Khong HT, McCarthy J. Chlorambucil-induced pulmonary disease: a case report and review of the literature. Ann Hematol. 1998 Jul;77(1-2):85-87. Pubmedid: 9760160.
  • Thurber SE, Khong HT, Kammula US, Rosenberg SA. Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction. J Immunother. 25(1):63-71. Pubmedid: 11924911. Pmcid: PMC2424231.
  • Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother. 28(3):258-267. Pubmedid: 15838383. Pmcid: PMC2174599.
  • Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 27(6):472-477. Pubmedid: 15534491. Pmcid: PMC2227905.
  • Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother. 27(3):184-190. Pubmedid: 15076135. Pmcid: PMC2275330.
  • Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA. Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J Immunother. 29(4):398-406. Pubmedid: 16799335. Pmcid: PMC1510955.